PEDIATRICS Vol. 82 No. 1 July 1988, pp. 122
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Intravenous ggr-Globulin Use in Children With Kawasaki Disease

Committee on Infectious Diseases

A recent controlled American trial1 of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV ggr-globulin, which is not currently licensed in the United States. The dosage of IV ggr-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV ggr-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV ggr-globulin.2

Because the etiology of Kawasaki disease is not known and the active component of the immune globulin has not been identified, it is not known whether all IV ggr-globulin preparations currently licensed in the United States will be effective. Further studies are underway to compare different IV ggr-globulin preparations and to determine the optimal dose and schedule of administration.

Pediatricians should consider using IV ggr-globulin and aspirin for the treatment of patients who meet the strict criteria for this syndrome.3 If IV ggr-globulin is to be used, therapy should be initiated with any one of the products licensed in the United States and administered within ten days of the onset of illness at the dosage schedule described above. The efficacy of such therapy if initiated more than ten days after onset of illness or after aneurysms have been found has not yet been demonstrated.




This article has been cited by other articles:


Home page
 Vasc MedHome page
J. W Newburger and J. C Burns
Kawasaki disease
Vascular Medicine, August 1, 1999; 4(3): 187 - 202.
[Abstract] [PDF]

Home page
 Arch. Dis. Child.Home page
J. A Royle, K. Williams, E. Elliott, G. Sholler, T. Nolan, R. Allen, and D. Isaacs
Kawasaki disease in Australia, 1993-95
Arch. Dis. Child., January 1, 1998; 78(1): 33 - 39.
[Abstract] [Full Text]